{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:55:09Z","timestamp":1792716909429,"version":"4.5.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T00:00:00Z","timestamp":1645228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T00:00:00Z","timestamp":1645228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40257-022-00674-3","type":"journal-article","created":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T13:04:43Z","timestamp":1645275883000},"page":"339-352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3692-629X","authenticated-orcid":false,"given":"Laura","family":"Del Regno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Di Stefani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Cappilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,19]]},"reference":[{"key":"674_CR1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1067\/mjd.2000.107497","volume":"43","author":"MR Heaphy Jr","year":"2000","unstructured":"Heaphy MR Jr, Ackerman AB. The nature of solar keratosis: a critical review in historical perspective. J Am Acad Dermatol. 2000;43:138\u201350. https:\/\/doi.org\/10.1067\/mjd.2000.107497.","journal-title":"J Am Acad Dermatol"},{"key":"674_CR2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/bjd.12420","volume":"169","author":"RN Werner","year":"2013","unstructured":"Werner RN, Sammain A, Erdmann R, et al. The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013;169:502\u201318. https:\/\/doi.org\/10.1111\/bjd.12420.","journal-title":"Br J Dermatol"},{"key":"674_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2133.2005.07121.x","volume":"155","author":"AB Ackerman","year":"2006","unstructured":"Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol. 2006;155:9\u201322. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.07121.x.","journal-title":"Br J Dermatol"},{"key":"674_CR4","first-page":"201","volume":"87","author":"SR Feldman","year":"2011","unstructured":"Feldman SR, Fleischer AB Jr. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis. 2011;87:201\u20137.","journal-title":"Cutis"},{"key":"674_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2133.2007.08270.x","volume":"157","author":"C Ferrandiz","year":"2007","unstructured":"Ferrandiz C. Update on actinic keratosis in clinical trial experience with imiquimod. Br J Dermatol. 2007;157:32\u20133. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08270.x.","journal-title":"Br J Dermatol"},{"key":"674_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.clindermatol.2017.10.008","volume":"36","author":"V Lai","year":"2018","unstructured":"Lai V, Cranwell W, Sinclair R. Epidemiology of skin cancer in the mature patient. Clin Dermat. 2018;36:167\u201376. https:\/\/doi.org\/10.1016\/j.clindermatol.2017.10.008.","journal-title":"Clin Dermat"},{"key":"674_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1684\/ejd.2017.3126","volume":"27","author":"MC Fargnoli","year":"2017","unstructured":"Fargnoli MC, Altomare G, Benati E, et al. Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics. Eur J Dermatol. 2017;27:599\u2013608. https:\/\/doi.org\/10.1684\/ejd.2017.3126.","journal-title":"Eur J Dermatol"},{"key":"674_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1046\/j.1523-1747.2000.00048.x","volume":"115","author":"C Frost","year":"2000","unstructured":"Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a queensland community. J Invest Dermatol. 2000;115:273\u20137. https:\/\/doi.org\/10.1046\/j.1523-1747.2000.00048.x.","journal-title":"J Invest Dermatol"},{"key":"674_CR9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000112925","volume":"216","author":"P Bernard","year":"2008","unstructured":"Bernard P, Dupuy A, Sasco A, et al. Basal cell carcinomas and actinic keratoses seen in dermatological practice in France: a cross sectional survey. Dermatology. 2008;216:194\u20139. https:\/\/doi.org\/10.1159\/000112925.","journal-title":"Dermatology"},{"key":"674_CR10","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1111\/bjd.13132","volume":"171","author":"J Eder","year":"2014","unstructured":"Eder J, Prillinger K, Korn A, et al. Prevalence of actinic keratosis among dermatology outpatients in Austria. Br J Dermatol. 2014;171:1415\u201321. https:\/\/doi.org\/10.1111\/bjd.13132.","journal-title":"Br J Dermatol"},{"key":"674_CR11","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/jid.2013.134","volume":"133","author":"SC Flohil","year":"2013","unstructured":"Flohil SC, Van der Leest RJ, Dowlatshahi EA, et al. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study. J Investig Dermatol. 2013;133:1971\u20138. https:\/\/doi.org\/10.1038\/jid.2013.134.","journal-title":"J Investig Dermatol"},{"key":"674_CR12","doi-asserted-by":"publisher","unstructured":"Ferr\u00e1ndiz C, Plazas MJ, Sabat\u00e9 M, Palomino R, EPIQA Study Group. Prevalence of actinic keratosis among dermatology outpatients in Spain. Actas Dermosifiliogr 2016;107:674\u2013680. https:\/\/doi.org\/10.1016\/j.ad.2016.05.016","DOI":"10.1016\/j.ad.2016.05.016"},{"key":"674_CR13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/09546634.2016.1254328","volume":"28","author":"T Dirschka","year":"2017","unstructured":"Dirschka T, Gupta G, Micali G, et al. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. J Dermatol Treat. 2017;28:431\u201342. https:\/\/doi.org\/10.1080\/09546634.2016.1254328.","journal-title":"J Dermatol Treat"},{"key":"674_CR14","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1046\/j.1365-2133.2000.03541.x","volume":"142","author":"AA Memon","year":"2000","unstructured":"Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol. 2000;142:1154\u20139. https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03541.x.","journal-title":"Br J Dermatol"},{"key":"674_CR15","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/0190-9622(91)70113-g","volume":"24","author":"EA Olsen","year":"1991","unstructured":"Olsen EA, Abernethy ML, Kulp-Shorten C, et al. A double-blind, vehicle controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol. 1991;24:738\u201343. https:\/\/doi.org\/10.1016\/0190-9622(91)70113-g.","journal-title":"J Am Acad Dermatol"},{"key":"674_CR16","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/jdv.13626","volume":"30","author":"L Schmitz","year":"2016","unstructured":"Schmitz L, Kahl P, Majores M, et al. Actinic keratosis: correlation between clinical and histological classification systems. J Eur Acad Dermatol Venereol. 2016;30:1303\u20137. https:\/\/doi.org\/10.1111\/jdv.13626.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"674_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jdv.14151","volume":"31","author":"MT Fernandez Figueras","year":"2017","unstructured":"Fernandez Figueras MT. From actinic keratosis to squamous cell carcinoma: pathophysiology revisited. J Eur Acad Dermatol Venereol. 2017;31:5\u20137. https:\/\/doi.org\/10.1111\/jdv.14151.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"674_CR18","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/jdv.12848","volume":"29","author":"MT Fern\u00e1ndez-Figueras","year":"2015","unstructured":"Fern\u00e1ndez-Figueras MT, Carrato C, S\u00e1enz X, et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol. 2015;29:991\u20137. https:\/\/doi.org\/10.1111\/jdv.12848.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"674_CR19","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1111\/jdv.14901","volume":"32","author":"MT Fern\u00e1ndez-Figueras","year":"2018","unstructured":"Fern\u00e1ndez-Figueras MT, Saenz-Sard\u00e0 X, Vargas P, et al. The depth of follicular extension in actinic keratosis correlates with the depth of invasion in squamous cell carcinoma: implication for clinical treatment. J Eur Acad Dermatol Venereol. 2018;32:1657\u201361. https:\/\/doi.org\/10.1111\/jdv.14901.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"674_CR20","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1080\/09546634.2019.1679335","volume":"31","author":"WG Philipp-Dormston","year":"2020","unstructured":"Philipp-Dormston WG, Battistella M, Boussemart L, et al. Patient-centered management of actinic keratosis. Results of a multi-center clinical consensus analyzing non-melanoma skin cancer patient profiles and field-treatment strategies. J Dermatolog Treat. 2020;31:576\u201382. https:\/\/doi.org\/10.1080\/09546634.2019.1679335.","journal-title":"J Dermatolog Treat"},{"key":"674_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jaad.2020.03.126","volume":"83","author":"TJ Willenbrink","year":"2020","unstructured":"Willenbrink TJ, Ruiz ES, Cornejo CM, et al. Field cancerization: Definition, epidemiology, risk factors, and outcomes. J Am Acad Dermatol. 2020;83:709\u201317. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.126.","journal-title":"J Am Acad Dermatol"},{"key":"674_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00403-020-02104-y","volume":"313","author":"S Javor","year":"2021","unstructured":"Javor S, Gasparini G, Biatta CM, et al. P53 staining index and zonal staining patterns in actinic keratoses. Arch Dermatol Res. 2021;313:275\u20139. https:\/\/doi.org\/10.1007\/s00403-020-02104-y.","journal-title":"Arch Dermatol Res"},{"key":"674_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/srt.12913","volume":"27","author":"Z Tang","year":"2021","unstructured":"Tang Z, Kang L, Zhang Y, et al. The diagnostic value of in vivo reflectance confocal microscopy in actinic keratosis. Res Technol. 2021;27:80\u20135. https:\/\/doi.org\/10.1111\/srt.12913.","journal-title":"Res Technol"},{"key":"674_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13992","volume":"33","author":"E Moscarella","year":"2020","unstructured":"Moscarella E, Di Brizzi EV, Casari A, et al. Italian expert consensus paper on the management of patients with actinic keratoses. Dermatol Ther. 2020;33: e13992. https:\/\/doi.org\/10.1111\/dth.13992.","journal-title":"Dermatol Ther"},{"key":"674_CR25","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/ijd.14147","volume":"58","author":"ECV De Oliveira","year":"2019","unstructured":"De Oliveira ECV, Da Motta VRV, Pantoja PC, et al. Actinic keratosis\u2014review for clinical practice. Int J Dermatol. 2019;58:400\u20137. https:\/\/doi.org\/10.1111\/ijd.14147.","journal-title":"Int J Dermatol"},{"key":"674_CR26","doi-asserted-by":"publisher","first-page":"756","DOI":"10.36849\/JDD.2020.5123","volume":"19","author":"JB Hansen","year":"2020","unstructured":"Hansen JB, Larsson T, Dunkelly-Allen N, et al. Real-World effectiveness and safety of field- and lesion-directed treatments for actinic keratosis. J Drugs Dermatol. 2020;19:756\u201362. https:\/\/doi.org\/10.36849\/JDD.2020.5123.","journal-title":"J Drugs Dermatol"},{"key":"674_CR27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1365-2133.2007.07942.x","volume":"157","author":"A Alomar","year":"2007","unstructured":"Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol. 2007;157:133\u201341. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07942.x.","journal-title":"Br J Dermatol"},{"key":"674_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jaad.2007.01.047","volume":"57","author":"J Jorizzo","year":"2007","unstructured":"Jorizzo J, Dinehart S, Matheson R, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one of two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007;57:265\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2007.01.047.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"674_CR29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jaad.2009.06.020","volume":"62","author":"CW Hanke","year":"2010","unstructured":"Hanke CW, Beer KR, Stockfleth E, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol. 2010;62(4):573\u201381.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"674_CR30","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jaad.2009.07.004","volume":"62","author":"N Swanson","year":"2010","unstructured":"Swanson N, Abramovits W, Berman B, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62(4):582\u201390.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"674_CR31","first-page":"165","volume":"10","author":"CW Hanke","year":"2011","unstructured":"Hanke CW, Swanson N, Bruce S, et al. Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream. J Drugs Dermatol. 2011;10(2):165\u201370.","journal-title":"J Drugs Dermatol"},{"key":"674_CR32","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2340\/00015555-2710","volume":"97","author":"B Dr\u00e9no","year":"2017","unstructured":"Dr\u00e9no B, Cerio R, Dirschka T, et al. A novel actinic keratosis field assessment scale for grading actinic keratosis disease severity. Acta Derm Venereol. 2017;97:1108\u201313.","journal-title":"Acta Derm Venereol"},{"key":"674_CR33","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1056\/NEJMoa1811850","volume":"380","author":"MHE Jansen","year":"2019","unstructured":"Jansen MHE, Kessels JPHM, Nelemans PJ, et al. Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med. 2019;380:935\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1811850.","journal-title":"N Engl J Med"},{"key":"674_CR34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2133.2007.08271.x","volume":"157","author":"N Krawtchenko","year":"2007","unstructured":"Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs topical 5-fluorouracil vs cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157:34\u201340.","journal-title":"Br J Dermatol"},{"key":"674_CR35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1365-4632.2009.04045.x","volume":"48","author":"DA Askew","year":"2009","unstructured":"Askew DA, Mickan SM, Soyer HP, et al. Effectiveness of 5-fluorouracil treatment for actinic keratosis\u2014a systematic review of randomized controlled trials. Int J Dermatol. 2009;48:453\u201363.","journal-title":"Int J Dermatol"},{"key":"674_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12822","volume":"32","author":"Y Wu","year":"2019","unstructured":"Wu Y, Tang N, Cai L, et al. Relative efficacy of 5-fluorouracil compared with other treatments among patients with actinic keratosis: a network meta-analysis. Dermatol Ther. 2019;32: e12822. https:\/\/doi.org\/10.1111\/dth.12822.","journal-title":"Dermatol Ther"},{"key":"674_CR37","first-page":"285","volume":"18","author":"A Iglesias-Puzas","year":"2019","unstructured":"Iglesias-Puzas A, Batalla A, Suh-Oh HJ, et al. 0.5% 5-fluorouracil\/10% salicylic acid for the treatment of distal actinic keratoses under daily practice conditions. J Drugs Dermatol. 2019;18:285\u20138.","journal-title":"J Drugs Dermatol"},{"key":"674_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rmed.2016.07.004","volume":"118","author":"JHY Tan","year":"2016","unstructured":"Tan JHY, Hsu AAL. Nonsteroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease phenotype: topical NSAID and asthma control\u2014a possible oversight link. Respir Med. 2016;118:1\u20133. https:\/\/doi.org\/10.1016\/j.rmed.2016.07.004.","journal-title":"Respir Med"},{"issue":"11","key":"674_CR39","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.36849\/JDD.2020.5576","volume":"19","author":"S Kempers","year":"2020","unstructured":"Kempers S, DuBois J, Forman S, et al. Tirbanibulin ointment 1% as a novel treatment for actinic keratosis: phase 1 and 2 results. J Drugs Dermatol. 2020;19(11):1093\u2013100. https:\/\/doi.org\/10.36849\/JDD.2020.5576.","journal-title":"J Drugs Dermatol"},{"key":"674_CR40","first-page":"399","volume":"101","author":"KT Clebak","year":"2020","unstructured":"Clebak KT, Mendez-Miller M, Croad J. Cutaneous cryosurgery for common skin conditions. Am Fam Phys. 2020;101:399\u2013406.","journal-title":"Am Fam Phys"},{"key":"674_CR41","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/ddg.14048","volume":"18","author":"MV Heppt","year":"2020","unstructured":"Heppt MV, Leiter U, Steeb T, et al. S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma\u2014short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. J Dtsch Dermatol Ges. 2020;18:275\u201394. https:\/\/doi.org\/10.1111\/ddg.14048.","journal-title":"J Dtsch Dermatol Ges"},{"key":"674_CR42","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/jdv.16112","volume":"34","author":"C Maire","year":"2020","unstructured":"Maire C, Vignion-Dewalle AS, Cartier H, et al. Artificial white light photodynamic therapy for actinic keratosis: a study of 38 patients in private office practice. J Eur Acad Dermatol Venereol. 2020;34:165\u20137. https:\/\/doi.org\/10.1111\/jdv.16112.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"674_CR43","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/ijd.14767","volume":"59","author":"C Dianzani","year":"2020","unstructured":"Dianzani C, Conforti C, Giuffrida R, et al. Current therapies for actinic keratosis. Int J Dermatol. 2020;59:677\u201384. https:\/\/doi.org\/10.1111\/ijd.14767.","journal-title":"Int J Dermatol"},{"key":"674_CR44","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1111\/bjd.13138","volume":"171","author":"DM Rubel","year":"2014","unstructured":"Rubel DM, Spelman L, Murrell DF, et al. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. Br J Dermatol. 2014;171:1164\u201371. https:\/\/doi.org\/10.1111\/bjd.13138.","journal-title":"Br J Dermatol"},{"key":"674_CR45","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1524-4725.1997.tb00020.x","volume":"23","author":"DD Witheiler","year":"1997","unstructured":"Witheiler DD, Lawrence N, Cox SE, et al. Long-term efficacy and safety of Jessner\u2019s solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg. 1997;23:191\u20136. https:\/\/doi.org\/10.1111\/j.1524-4725.1997.tb00020.x.","journal-title":"Dermatol Surg"},{"key":"674_CR46","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3109\/09546634.2012.757285","volume":"25","author":"S Esmann","year":"2014","unstructured":"Esmann S, Jemec GB. Patients\u2019 perceptions of topical treatments of actinic keratosis. J Dermatol Treat. 2014;25:375\u20139. https:\/\/doi.org\/10.3109\/09546634.2012.757285.","journal-title":"J Dermatol Treat"},{"issue":"5","key":"674_CR47","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/bjd.14680","volume":"175","author":"S Erntoft","year":"2016","unstructured":"Erntoft S, Norlin J, Pollard C, Diepgen T. Patient-reported adherence and persistence to topical treatments for actinic keratosis: a longitudinal diary study. Br J Dermatol. 2016;175(5):1094\u20136.","journal-title":"Br J Dermatol"},{"issue":"8","key":"674_CR48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/PPA.S47126.PMID:24379656;PMCID:PMC3872140","volume":"17","author":"B Shergill","year":"2013","unstructured":"Shergill B, Zokaie S, Carr AJ. Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adherence. 2013;17(8):35\u201341. https:\/\/doi.org\/10.2147\/PPA.S47126.PMID:24379656;PMCID:PMC3872140.","journal-title":"Patient Prefer Adherence"},{"issue":"965","key":"674_CR49","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jaad.2013.12.045","volume":"70","author":"G Micali","year":"2014","unstructured":"Micali G, Lacarrubba F, Nasca MR, et al. Topical pharmacotherapy for skin cancer: part I. Pharmacology. J Am Acad Dermatol. 2014;70(965):e1-12. https:\/\/doi.org\/10.1016\/j.jaad.2013.12.045.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"674_CR50","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4103\/0253-7613.161249","volume":"47","author":"AK Bubna","year":"2015","unstructured":"Bubna AK. Imiquimod\u2014its role in the treatment of cutaneous malignancies. Indian J Pharmacol. 2015;47(4):354\u20139. https:\/\/doi.org\/10.4103\/0253-7613.161249.","journal-title":"Indian J Pharmacol."},{"key":"674_CR51","first-page":"166","volume":"13","author":"N Swanson","year":"2014","unstructured":"Swanson N, Smith CC, Kaur M, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Drugs Dermatol. 2014;13:166\u20139.","journal-title":"J Drugs Dermatol"},{"key":"674_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2021.1917758","volume":"2021","author":"VK Emmerich","year":"2021","unstructured":"Emmerich VK, Cull D, Kelly KA, et al. Patient assessment of 5-fluorouracil and imiquimod for the treatment of actinic keratoses: a retrospective study of real-world effectiveness. J Dermatol Treat. 2021;2021:1\u20134. https:\/\/doi.org\/10.1080\/09546634.2021.1917758.","journal-title":"J Dermatol Treat"},{"key":"674_CR53","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/jdv.13648","volume":"30","author":"K Peris","year":"2016","unstructured":"Peris K, Calzavara-Pinton PG, Neri L, et al. Italian expert consensus for the management of actinic keratosis in immunocompetent patients. J Eur Acad Dermatol Venereol. 2016;30:1077\u201384. https:\/\/doi.org\/10.1111\/jdv.13648.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"674_CR54","doi-asserted-by":"publisher","first-page":"1829884","DOI":"10.1080\/20016689.2020.1829884","volume":"8","author":"K Ezzedine","year":"2020","unstructured":"Ezzedine K, Painchault C, Brignone M. Use of complete clearance for assessing treatment efficacy for 5-fluorouracil interventions in actinic keratoses: how baseline lesion count can impact this outcome. J Mark Access Health Policy. 2020;8:1829884. https:\/\/doi.org\/10.1080\/20016689.2020.1829884.","journal-title":"J Mark Access Health Policy."},{"key":"674_CR55","first-page":"335","volume":"70","author":"J Jorizzo","year":"2002","unstructured":"Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis. 2002;70:335\u20139.","journal-title":"Cutis"},{"key":"674_CR56","first-page":"22","volume":"70","author":"J Weiss","year":"2002","unstructured":"Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70:22\u20139.","journal-title":"Cutis"},{"key":"674_CR57","first-page":"1218","volume":"15","author":"MA Dohil","year":"2016","unstructured":"Dohil MA. Efficacy, safety, and tolerability of 4% 5-fluorouracil cream in a novel patented aqueous cream containing peanut oil once daily compared with 5% 5-fluorouracil cream twice daily: meeting the challenge in the treatment of actinic keratosis. J Drugs Dermatol. 2016;15:1218\u201324.","journal-title":"J Drugs Dermatol"},{"key":"674_CR58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s13555-016-0161-2","volume":"7","author":"E Stockfleth","year":"2017","unstructured":"Stockfleth E, von Kiedrowski R, Dominicus R, et al. Efficacy and safety of 5-fluorouracil 0.5%\/salicylic acid 10% in the field-directed treatment of actinic keratosis: a phase III, randomized, double-blind, vehicle-controlled trial. Dermatol Ther Heidelb. 2017;7:81\u201396.","journal-title":"Dermatol Ther Heidelb."},{"key":"674_CR59","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/j.1365-2133.2011.10387.x","volume":"165","author":"E Stockfleth","year":"2011","unstructured":"Stockfleth E, Kerl H, Zwingers T, et al. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol. 2011;165:1101\u20138. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10387.x.","journal-title":"Br J Dermatol"},{"key":"674_CR60","first-page":"401","volume":"3","author":"C Nelson","year":"2004","unstructured":"Nelson C, Rigel D, Smith S, et al. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol. 2004;3:401\u20137.","journal-title":"J Drugs Dermatol"},{"key":"674_CR61","doi-asserted-by":"publisher","first-page":"CD004415","DOI":"10.1002\/14651858.CD004415.pub2","volume":"12","author":"AK Gupta","year":"2012","unstructured":"Gupta AK, Paquet M, Villanueva E, et al. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012;12:CD004415. https:\/\/doi.org\/10.1002\/14651858.CD004415.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"674_CR62","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/2058738418757925","volume":"32","author":"S Nistic\u00f2","year":"2018","unstructured":"Nistic\u00f2 S, Del-Duca E, Torchia V, et al. Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis. Int J Immunopathol Pharmacol. 2018;32:925. https:\/\/doi.org\/10.1177\/2058738418757925.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"674_CR63","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.3390\/jcm9072253","volume":"9","author":"T Steeb","year":"2020","unstructured":"Steeb T, Wessely A, Harla\u00df M, et al. A systematic review and meta-analysis of interventions for actinic keratosis from post-marketing surveillance trials. J Clin Med. 2020;9:2253. https:\/\/doi.org\/10.3390\/jcm9072253.","journal-title":"J Clin Med"},{"key":"674_CR64","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1080\/03007995.2016.1174678","volume":"32","author":"G Babino","year":"2016","unstructured":"Babino G, Diluvio L, Bianchi L, et al. Long-term use of a new topical formulation containing piroxicam 0.8% and sunscreen: efficacy and tolerability on actinic keratosis. A proof of concept study. Curr Med Res Opin. 2016;32:1345\u20139. https:\/\/doi.org\/10.1080\/03007995.2016.1174678.","journal-title":"Curr Med Res Opin"},{"key":"674_CR65","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1056\/NEJMoa2024040","volume":"384","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Kempers S, Lain E, et al. Phase 3 trials of tirbanibulin ointment for actinic keratosis. N Engl J Med. 2021;384:512\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2024040.","journal-title":"N Engl J Med"},{"key":"674_CR66","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40265-021-01479-0","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A, Duggan S. Tirbanibulin: first approval. Drugs. 2021;81:509\u201313.","journal-title":"Drugs"},{"key":"674_CR67","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/bjd.17632","volume":"181","author":"EC Noels","year":"2019","unstructured":"Noels EC, Hollestein LM, Van Egmond S, et al. Healthcare utilization and management of actinic keratosis in primary and secondary care: a complementary database analysis. Br J Dermatol. 2019;181:544\u201353. https:\/\/doi.org\/10.1111\/bjd.17632.","journal-title":"Br J Dermatol"},{"key":"674_CR68","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/bjd.17435","volume":"180","author":"MV Heppt","year":"2019","unstructured":"Heppt MV, Steeb T, Ruzicka T, et al. Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis. Br J Dermatol. 2019;180:740\u20138. https:\/\/doi.org\/10.1111\/bjd.17435.","journal-title":"Br J Dermatol"},{"key":"674_CR69","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/j.1365-2133.2008.08488.x","volume":"158","author":"R Kaufmann","year":"2008","unstructured":"Kaufmann R, Spelman L, Weightman W, et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol. 2008;158:994\u20139. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08488.x.","journal-title":"Br J Dermatol"},{"key":"674_CR70","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/jdv.12702","volume":"29","author":"JC Simon","year":"2015","unstructured":"Simon JC, Dominicus R, Karl L, et al. A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU\/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. J Eur Acad Dermatol Venereol. 2015;29:881\u20139. https:\/\/doi.org\/10.1111\/jdv.12702.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"674_CR71","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/bjd.12847","volume":"170","author":"C Zane","year":"2014","unstructured":"Zane C, Facchinetti E, Rossi MT, et al. Cryotherapy is preferable to ablative CO2 laser for the treatment of isolated actinic keratoses of the face and scalp: a randomized clinical trial. Br J Dermatol. 2014;170:1114\u201321. https:\/\/doi.org\/10.1111\/bjd.12847.","journal-title":"Br J Dermatol"},{"key":"674_CR72","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2133.2007.08271.x","volume":"157","author":"N Krawtchenko","year":"2007","unstructured":"Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157:34\u201340. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08271.x.","journal-title":"Br J Dermatol"},{"key":"674_CR73","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/DSS.0000000000000989","volume":"43","author":"B Berman","year":"2017","unstructured":"Berman B, Shabbir AQ, MacNeil T, et al. Variables in cryosurgery technique associated with clearance of actinic keratosis. Dermatol Surg. 2017;43:424\u201330. https:\/\/doi.org\/10.1097\/DSS.0000000000000989.","journal-title":"Dermatol Surg"},{"key":"674_CR74","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1365-4632.2004.02056.x","volume":"43","author":"KE Thai","year":"2004","unstructured":"Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004;43:687\u201392. https:\/\/doi.org\/10.1111\/j.1365-4632.2004.02056.x.","journal-title":"Int J Dermatol"},{"key":"674_CR75","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bjd.15107","volume":"176","author":"D De Berker","year":"2017","unstructured":"De Berker D, McGregor JM, Mohd Mustapa MF, et al. British Association of Dermatologists\u2019 guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol. 2017;176:20\u201343. https:\/\/doi.org\/10.1111\/bjd.15107.","journal-title":"Br J Dermatol"},{"key":"674_CR76","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1046\/j.1524-4725.2000.99197.x","volume":"26","author":"SE Chiarello","year":"2000","unstructured":"Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. Dermatol Surg. 2000;26:728\u201332. https:\/\/doi.org\/10.1046\/j.1524-4725.2000.99197.x.","journal-title":"Dermatol Surg"},{"key":"674_CR77","first-page":"1049","volume":"10","author":"AF Taub","year":"2011","unstructured":"Taub AF, Garretson CB. A randomized, blinded, bilateral intraindividual, vehicle-controlled trial of the use of photodynamic therapy with 5-aminolevulinic acid and blue light for the treatment of actinic keratoses of the upper extremities. J Drugs Dermatol. 2011;10:1049\u201356.","journal-title":"J Drugs Dermatol"},{"key":"674_CR78","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/j.1365-2133.2006.07520.x","volume":"155","author":"EH Tschen","year":"2006","unstructured":"Tschen EH, Wong DS, Pariser DM, et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol. 2006;155:1262\u20139. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07520.x.","journal-title":"Br J Dermatol"},{"key":"674_CR79","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/j.1365-2133.2009.09119.x","volume":"160","author":"SR Wiegell","year":"2009","unstructured":"Wiegell SR, Haedersdal M, Eriksen P, et al. Photodynamic therapy of actinic keratoses with 8% and 16% methyl aminolaevulinate and home-based daylight exposure: a double-blinded randomized clinical trial. Br J Dermatol. 2009;160:1308\u201314. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09119.x.","journal-title":"Br J Dermatol"},{"key":"674_CR80","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-2133.2012.11200.x","volume":"168","author":"SR Wiegell","year":"2013","unstructured":"Wiegell SR, Fabricius S, Heydenreich J, et al. Weather conditions and daylight-mediated photodynamic therapy: protoporphyrin IX-weighted daylight doses measured in six geographical locations. Br J Dermatol. 2013;168:186\u201391. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11200.x.","journal-title":"Br J Dermatol"},{"issue":"3","key":"674_CR81","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/ijms17030309","volume":"17","author":"CM Lerche","year":"2016","unstructured":"Lerche CM, Heerfordt IM, Heydenreich J, Wulf HC. Alternatives to outdoor daylight illumination for photodynamic therapy-use of greenhouses and artificial light sources. Int J Mol Sci. 2016;17(3):309. https:\/\/doi.org\/10.3390\/ijms17030309.","journal-title":"Int J Mol Sci"},{"key":"674_CR82","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.pdpdt.2018.06.013","volume":"23","author":"P O\u2019Mahoney","year":"2018","unstructured":"O\u2019Mahoney P, Haigh N, Wood K, et al. A novel light source with tuneable uniformity of light distribution for artificial daylight photodynamic therapy. Photodiagn Photodyn Ther. 2018;23:144\u201350. https:\/\/doi.org\/10.1016\/j.pdpdt.2018.06.013.","journal-title":"Photodiagn Photodyn Ther"},{"key":"674_CR83","doi-asserted-by":"publisher","first-page":"636","DOI":"10.23736\/S0392-0488.20.06598-0","volume":"155","author":"A Dattola","year":"2020","unstructured":"Dattola A, Guti\u00e9rrez Garc\u00eca-Rodrigo C, Tambone S, et al. 5-Aminolaevulinic acid patch photodynamic therapy for the treatment of actinic keratoses: preliminary results from an Italian study in the real-life setting. G Ital Dermatol Venereol. 2020;155:636\u201341. https:\/\/doi.org\/10.23736\/S0392-0488.20.06598-0.","journal-title":"G Ital Dermatol Venereol"},{"key":"674_CR84","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjd.18048","volume":"182","author":"S Mordon","year":"2020","unstructured":"Mordon S, Vignion-Dewalle AS, Abi-Rached H, et al. The conventional protocol vs a protocol including illumination with a fabric-based biophotonic device (the Phosistos protocol) in photodynamic therapy for actinic keratosis: a randomized, controlled, noninferiority clinical study. Br J Dermatol. 2020;182:76\u201384. https:\/\/doi.org\/10.1111\/bjd.18048.","journal-title":"Br J Dermatol"},{"key":"674_CR85","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.3390\/cancers13174447","volume":"13","author":"JF Algorri","year":"2021","unstructured":"Algorri JF, Ochoa M, Rold\u00e1n-Varona P, Rodr\u00edguez-Cobo L, L\u00f3pez-Higuera JM, et al. Photodynamic therapy: a compendium of latest reviews. Cancers (Basel). 2021;13:4447. https:\/\/doi.org\/10.3390\/cancers13174447.","journal-title":"Cancers (Basel)"},{"key":"674_CR86","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1001\/archderm.1995.01690140060009","volume":"131","author":"N Lawrence","year":"1995","unstructured":"Lawrence N, Cox SE, Cockerell CJ, et al. A comparison of the efficacy and safety of Jessner\u2019s solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol. 1995;131:176\u201381.","journal-title":"Arch Dermatol"},{"key":"674_CR87","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/jdv.16844","volume":"35","author":"T Steeb","year":"2021","unstructured":"Steeb T, Koch EAT, Wessely A, et al. Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35:641\u20139. https:\/\/doi.org\/10.1111\/jdv.16844.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"674_CR88","doi-asserted-by":"publisher","first-page":"120347542110275","DOI":"10.1177\/12034754211027515","volume":"2021","author":"F Tai","year":"2021","unstructured":"Tai F, Shah M, Pon K, et al. Laser resurfacing monotherapy for the treatment of actinic keratosis. J Cutan Med Surg. 2021;2021:12034754211027516. https:\/\/doi.org\/10.1177\/12034754211027515.","journal-title":"J Cutan Med Surg"},{"key":"674_CR89","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jaad.2019.07.106","volume":"83","author":"M Lai","year":"2020","unstructured":"Lai M, Pampena R, Cornacchia L, et al. Treatments of actinic cheilitis: a systematic review of the literature. J Am Acad Dermatol. 2020;83:876\u201387. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.106.","journal-title":"J Am Acad Dermatol"},{"key":"674_CR90","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1177\/1203475417708166","volume":"21","author":"P Fleming","year":"2017","unstructured":"Fleming P, Zhou S, Bobotsis R, et al. Comparison of the treatment guidelines for actinic keratosis: a critical appraisal and review. J Cutan Med Surg. 2017;21:408\u201317. https:\/\/doi.org\/10.1177\/1203475417708166.","journal-title":"J Cutan Med Surg"},{"key":"674_CR91","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/jdv.15459","volume":"33","author":"MV Heppt","year":"2019","unstructured":"Heppt MV, Steeb T, Leiter U, et al. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol. 2019;33:863\u201373. https:\/\/doi.org\/10.1111\/jdv.15459.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"674_CR92","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/jdv.15998","volume":"34","author":"T Steeb","year":"2020","unstructured":"Steeb T, Wessely A, Leiter U, et al. The more the better? An appraisal of combination therapies for actinic keratosis. J Eur Acad Dermatol Venereol. 2020;34:727\u201332. https:\/\/doi.org\/10.1111\/jdv.15998.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"674_CR93","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1097\/DSS.0000000000000589","volume":"42","author":"A Jambusaria-Pahlajani","year":"2016","unstructured":"Jambusaria-Pahlajani A, Ortman S, Schmults CD, et al. Sequential curettage, 5 fluorouracil, and photodynamic therapy for field cancerization of the scalp and face in solid organ transplant recipients. Dermatol Surg. 2016;42:S66\u201372. https:\/\/doi.org\/10.1097\/DSS.0000000000000589.","journal-title":"Dermatol Surg"},{"key":"674_CR94","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.13449","volume":"30","author":"P Gholam","year":"2016","unstructured":"Gholam P, Fink C, Bosselmann I, et al. Retrospective analysis evaluating the effect of a keratolytic and physical pretreatment with salicylic acid, urea and curettage on the efficacy and safety of photodynamic therapy of actinic keratoses with methylaminolaevulinate. J Eur Acad Dermatol Venereol. 2016;30:619\u201323. https:\/\/doi.org\/10.1111\/jdv.13449.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"674_CR95","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/bjc.2013.760","volume":"110","author":"SR Lambert","year":"2014","unstructured":"Lambert SR, Mladkova N, Gulati A, et al. Key differences identified between actinic keratosis and cutaneous squamous cell carcinoma by transcriptome profiling. Br J Cancer. 2014;110:520\u20139. https:\/\/doi.org\/10.1038\/bjc.2013.760.","journal-title":"Br J Cancer"},{"key":"674_CR96","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/14728214.2020.1730810","volume":"25","author":"P Cramer","year":"2020","unstructured":"Cramer P, Stockfleth E. Actinic keratosis: where do we stand and where is the future going to take us? Expert Opin Emerg Drugs. 2020;25:49\u201358. https:\/\/doi.org\/10.1080\/14728214.2020.1730810.","journal-title":"Expert Opin Emerg Drugs"},{"key":"674_CR97","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1365-2133.2008.08615.x","volume":"159","author":"RM Szeimies","year":"2008","unstructured":"Szeimies RM, Bichel J, Ortonne JP, et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol. 2008;159:205\u201310. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08615.x.","journal-title":"Br J Dermatol"},{"key":"674_CR98","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjd.17124","volume":"180","author":"E Stockfleth","year":"2019","unstructured":"Stockfleth E, Hofbauer GFL, Reinhold U, et al. Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo-controlled, double-blind clinical trial. Br J Dermatol. 2019;180:297\u2013305. https:\/\/doi.org\/10.1111\/bjd.17124.","journal-title":"Br J Dermatol"},{"key":"674_CR99","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/bjd.17436","volume":"180","author":"R Rajaratnam","year":"2019","unstructured":"Rajaratnam R. Resiquimod for actinic keratosis: is this a new treatment option? Br J Dermatol. 2019;180:254\u20135. https:\/\/doi.org\/10.1111\/bjd.17436.","journal-title":"Br J Dermatol"},{"key":"674_CR100","unstructured":"Safety and Efficacy Study of AM001 cream in the treatment of actinic keratosis [Internet]. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03210740. Accessed 31 Dec 2019."},{"key":"674_CR101","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/bjd.13342","volume":"172","author":"A Pflugfelder","year":"2015","unstructured":"Pflugfelder A, Andonov E, Weide B, et al. Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo-controlled double-blind phase II trial. Br J Dermatol. 2015;172:926\u201332. https:\/\/doi.org\/10.1111\/bjd.13342.","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"674_CR102","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jdv.14091","volume":"31","author":"R Cerio","year":"2017","unstructured":"Cerio R. The importance of patient-centred care to overcome barriers in the management of actinic keratosis. J Eur Acad Dermatol Venereol. 2017;31(Suppl 2):17\u201320. https:\/\/doi.org\/10.1111\/jdv.14091.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"674_CR103","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12877-020-1476-5","volume":"20","author":"K Thorell","year":"2020","unstructured":"Thorell K, Midl\u00f6v P, Fastbom J, Halling A. Use of potentially inappropriate medication and polypharmacy in older adults: a repeated cross-sectional study. BMC Geriatr. 2020;20(1):73. https:\/\/doi.org\/10.1186\/s12877-020-1476-5.","journal-title":"BMC Geriatr"},{"issue":"1","key":"674_CR104","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/jdv.15142","volume":"33","author":"L Neri","year":"2019","unstructured":"Neri L, Peris K, Longo C, Actinic Keratosis\u2014TReatment Adherence INitiative (AK-TRAIN) study group, et al. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy. J Eur Acad Dermatol Venereol. 2019;33(1):93\u2013107. https:\/\/doi.org\/10.1111\/jdv.15142.","journal-title":"J Eur Acad Dermatol Venereol"}],"updated-by":[{"DOI":"10.1007\/s40257-022-00682-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000}}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00674-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00674-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00674-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T09:12:03Z","timestamp":1653642723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00674-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,19]]},"references-count":104,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["674"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00674-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40257-022-00682-3","asserted-by":"object"}]},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,19]]},"assertion":[{"value":"24 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-022-00682-3","URL":"https:\/\/doi.org\/10.1007\/s40257-022-00682-3","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was provided for this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Laura Del Regno, Silvia Catapano, Alessandro Di Stefani and Simone Cappilli have no conflicts of interest that are directly relevant to the content of this article. Ketty Peris has received grants and personal fees from Almirall, AbbVie, Biogen, Lilly, Celgene, Galderma, Leo Pharma, Novartis, Pierre Fabre, Sanofi, Sandoz, Sun Pharma, and Janssen, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LDR, SCat, and KP contributed substantially to the conception of the paper and the acquisition and analysis of data. LDR and SCap drafted the manuscript. ADS and KP reviewed it critically and approved the final version for publication. All authors are responsible for the accuracy and integrity of any part of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}